ES2592957T3 - Biomarcadores para la predicción de la eficacia de una inmunoterapia contra el cáncer - Google Patents
Biomarcadores para la predicción de la eficacia de una inmunoterapia contra el cáncer Download PDFInfo
- Publication number
- ES2592957T3 ES2592957T3 ES11788121.9T ES11788121T ES2592957T3 ES 2592957 T3 ES2592957 T3 ES 2592957T3 ES 11788121 T ES11788121 T ES 11788121T ES 2592957 T3 ES2592957 T3 ES 2592957T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- cancer
- biomarker
- immunotherapy
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000090 biomarker Substances 0.000 title description 41
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 15
- 230000004044 response Effects 0.000 abstract description 13
- 210000002966 serum Anatomy 0.000 abstract description 12
- 230000004083 survival effect Effects 0.000 abstract description 10
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 239000003550 marker Substances 0.000 abstract description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 3
- 206010017758 gastric cancer Diseases 0.000 abstract description 3
- 201000011549 stomach cancer Diseases 0.000 abstract description 3
- 238000002255 vaccination Methods 0.000 abstract description 3
- 208000005017 glioblastoma Diseases 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 abstract 6
- 238000009169 immunotherapy Methods 0.000 abstract 4
- 230000009286 beneficial effect Effects 0.000 abstract 3
- 238000003018 immunoassay Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 abstract 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 2
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 2
- 239000000523 sample Substances 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- 238000002965 ELISA Methods 0.000 abstract 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 abstract 1
- 206010053759 Growth retardation Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 238000007419 epigenetic assay Methods 0.000 abstract 1
- 238000010195 expression analysis Methods 0.000 abstract 1
- 239000012520 frozen sample Substances 0.000 abstract 1
- 231100000001 growth retardation Toxicity 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 210000002751 lymph Anatomy 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000011325 microbead Substances 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 238000004611 spectroscopical analysis Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 7
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 6
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 6
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 6
- 229960004397 cyclophosphamide Drugs 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 5
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 4
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- PCLCDPVEEFVAAQ-UHFFFAOYSA-N BCA 1 Chemical compound CC(CO)CCCC(C)C1=CCC(C)(O)C1CC2=C(O)C(O)CCC2=O PCLCDPVEEFVAAQ-UHFFFAOYSA-N 0.000 description 3
- 238000001790 Welch's t-test Methods 0.000 description 3
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 238000008789 Direct Bilirubin Methods 0.000 description 2
- 229940124672 IMA901 Drugs 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 101710108790 Stromelysin-1 Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 108010016032 IMA950 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41698110P | 2010-11-24 | 2010-11-24 | |
| US416981P | 2010-11-24 | ||
| GBGB1021289.2A GB201021289D0 (en) | 2010-12-15 | 2010-12-15 | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| GB201021289 | 2010-12-15 | ||
| US42365210P | 2010-12-16 | 2010-12-16 | |
| US423652P | 2010-12-16 | ||
| PCT/EP2011/070661 WO2012069462A1 (en) | 2010-11-24 | 2011-11-22 | Biomarkers for predicting the efficacy of an immunotherapy against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2592957T3 true ES2592957T3 (es) | 2016-12-02 |
Family
ID=43567254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11788121.9T Active ES2592957T3 (es) | 2010-11-24 | 2011-11-22 | Biomarcadores para la predicción de la eficacia de una inmunoterapia contra el cáncer |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8669063B2 (enExample) |
| EP (1) | EP2643698B1 (enExample) |
| JP (1) | JP6005051B2 (enExample) |
| KR (1) | KR20130119453A (enExample) |
| CN (1) | CN103384827B (enExample) |
| AU (1) | AU2011333819A1 (enExample) |
| BR (1) | BR112013012820A2 (enExample) |
| CA (1) | CA2818738A1 (enExample) |
| EA (1) | EA201390762A1 (enExample) |
| ES (1) | ES2592957T3 (enExample) |
| GB (1) | GB201021289D0 (enExample) |
| HU (1) | HUE030005T2 (enExample) |
| MX (1) | MX341734B (enExample) |
| NZ (1) | NZ609712A (enExample) |
| PL (1) | PL2643698T3 (enExample) |
| SG (1) | SG190698A1 (enExample) |
| WO (1) | WO2012069462A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| US9026531B2 (en) * | 2012-04-17 | 2015-05-05 | Cerner Innovation, Inc. | Associating multiple data sources into a web-accessible framework |
| EP2864792A1 (en) | 2012-06-26 | 2015-04-29 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| CN103048453B (zh) * | 2012-12-18 | 2014-11-26 | 苏州浩欧博生物医药有限公司 | 一种糖类抗原ca19-9的纳米磁微粒化学发光测定试剂盒及其制备方法和检测方法 |
| RU2677742C2 (ru) | 2013-11-07 | 2019-01-21 | Медиал Рисеч Лтд. | Способы и системы оценки риска развития злокачественной опухоли легкого |
| EP2942629A1 (en) * | 2014-05-08 | 2015-11-11 | Universität Würzburg | Predictive markers for successful cancer immunotherapy |
| GB201505585D0 (en) * | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| WO2017008046A1 (en) * | 2015-07-08 | 2017-01-12 | Children's Hospital Medical Center | Loss of transcriptional fidelity leads to immunotherapy resistance in cancers |
| CN112710723B (zh) * | 2015-07-13 | 2024-11-12 | 佰欧迪塞克斯公司 | 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法 |
| CN108601731A (zh) | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
| WO2017136139A1 (en) | 2016-02-01 | 2017-08-10 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy |
| CN105624110A (zh) * | 2016-02-29 | 2016-06-01 | 时宏珍 | Hla-a0201限制性抗psa抗原特异性ctl的制备方法 |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| CN109690314B (zh) * | 2016-05-09 | 2022-08-02 | 法国国家卫生及研究医学协会 | 患有实体癌症的患者的分类方法 |
| US20190177430A1 (en) * | 2016-08-24 | 2019-06-13 | The Wistar Institute Of Anatomy And Biology | Methods of Treating Cancers With Chemotherapy With Reduced Toxicity |
| CN106198987A (zh) * | 2016-08-31 | 2016-12-07 | 辽宁迈迪生物科技股份有限公司 | 一种用于评价肿瘤免疫细胞疗法的检测标记物及其检测方法和应用 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| EP3566054A4 (en) * | 2017-01-05 | 2020-12-09 | Biodesix, Inc. | PROCESS FOR IDENTIFYING CANCER PATIENTS LIKELY TO BENEFIT FROM IMMUNOTHERAPY FOR LASTING SUSTAINABLE SUB-GROUPS OF PATIENTS WHO HAVE A BAD PROGNOSIS GENERALLY |
| US10699007B2 (en) * | 2017-03-13 | 2020-06-30 | Oracle International Corporation | Hybrid univariate/multivariate prognostic-surveillance technique |
| WO2018221820A1 (ko) * | 2017-06-02 | 2018-12-06 | 이종균 | 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트 |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| EP3773691A4 (en) | 2018-03-29 | 2022-06-15 | Biodesix, Inc. | Apparatus and method for identification of primary immune resistance in cancer patients |
| US20210263045A1 (en) * | 2018-04-06 | 2021-08-26 | The Board Of Regents Of The University Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
| CN108624650B (zh) * | 2018-05-14 | 2022-04-29 | 乐普（北京）医疗器械股份有限公司 | 判断实体瘤是否适合免疫治疗的方法和检测试剂盒 |
| CN110885886B (zh) * | 2018-09-07 | 2023-04-07 | 华中科技大学同济医学院附属协和医院 | 一种胶质母细胞瘤鉴别诊断及胶质瘤生存预后的分型方法 |
| KR102159538B1 (ko) * | 2019-01-11 | 2020-09-24 | 충남대학교 산학협력단 | 폐암 환자의 면역항암제에 대한 치료 반응성 예측용 il-6 마커 및 이의 용도 |
| EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
| CN113614537B (zh) * | 2019-03-28 | 2025-10-17 | 豪夫迈·罗氏有限公司 | 癌症预后 |
| CN111257563B (zh) * | 2020-01-22 | 2022-08-23 | 广州泛恩生物科技有限公司 | Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途 |
| EP4168802A4 (en) * | 2020-06-21 | 2025-03-19 | Oncohost Ltd | HOST SIGNATURES THAT PREDICTE IMMUNOTHERAPY RESPONSE |
| WO2022006514A1 (en) * | 2020-07-02 | 2022-01-06 | Gopath Laboratories Llc | Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer |
| US20230266337A1 (en) * | 2020-07-10 | 2023-08-24 | Sekisui Medical Co., Ltd. | Composition containing tarc, and method for improving storage stability of tarc |
| CN113219173A (zh) * | 2021-05-11 | 2021-08-06 | 中南大学湘雅医院 | Sh2b1在肺癌诊断中的应用 |
| CN113462776B (zh) * | 2021-06-25 | 2023-03-28 | 复旦大学附属肿瘤医院 | m6A修饰相关联合基因组在预测肾透明细胞癌患者免疫治疗疗效中的应用 |
| CN115058440B (zh) * | 2022-06-08 | 2023-08-15 | 郑州轻工业大学 | 催化合成天然蔗糖酯的工程菌及其构建方法和应用 |
| CN115612737A (zh) * | 2022-08-03 | 2023-01-17 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 一种胃癌免疫治疗疗效预测和预后评估的方法及其应用 |
| CN118072954A (zh) * | 2024-02-06 | 2024-05-24 | 江南大学附属医院 | 一种基于trp评分系统的胃癌免疫治疗反应预测方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| JP3490893B2 (ja) * | 1998-06-02 | 2004-01-26 | 富士レビオ株式会社 | 胃癌の診断方法 |
| WO2005098446A2 (en) * | 2004-03-31 | 2005-10-20 | The Johns Hopkins University | Biomarkers for ovarian cancer |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| BRPI0618564A2 (pt) * | 2005-11-02 | 2011-09-06 | Bayer Healthcare Llc | métodos para predição e prognóstico de cáncer e para monitoração de terapia contra cáncer |
| US20090035801A1 (en) * | 2005-12-27 | 2009-02-05 | Power3 Medical Products, Inc. | Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer |
| WO2007127749A2 (en) * | 2006-04-24 | 2007-11-08 | Critical Care Diagnostics, Inc. | Predicting mortality and detecting severe disease |
| AT504231A1 (de) * | 2006-10-03 | 2008-04-15 | Hans Dr Loibner | Prädiktive parameter |
| WO2009015841A1 (en) * | 2007-07-27 | 2009-02-05 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| EP2080812A1 (en) * | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| EP2105740A1 (en) * | 2008-03-28 | 2009-09-30 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Biomarkers for monitoring or predicting the treatment of cancer |
| RU2011101378A (ru) | 2008-06-16 | 2012-07-27 | Сайвидон Дайагностикс Гмбх (De) | Алгоритмы предсказания исхода у пациентов с узловой формой рака молочной железы после химиотерапии |
| WO2010076322A1 (en) | 2008-12-30 | 2010-07-08 | Siemens Healthcare Diagnostics Inc. | Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer |
| US20100240546A1 (en) * | 2009-03-20 | 2010-09-23 | Samuel Chun Lap Lo | Use of biomarkers for the diagnosis and prognosis of lung cancer |
-
2010
- 2010-12-15 GB GBGB1021289.2A patent/GB201021289D0/en not_active Ceased
-
2011
- 2011-11-22 US US13/302,674 patent/US8669063B2/en active Active
- 2011-11-22 ES ES11788121.9T patent/ES2592957T3/es active Active
- 2011-11-22 KR KR1020137015847A patent/KR20130119453A/ko not_active Ceased
- 2011-11-22 JP JP2013540324A patent/JP6005051B2/ja not_active Expired - Fee Related
- 2011-11-22 HU HUE11788121A patent/HUE030005T2/en unknown
- 2011-11-22 SG SG2013035530A patent/SG190698A1/en unknown
- 2011-11-22 NZ NZ609712A patent/NZ609712A/en not_active IP Right Cessation
- 2011-11-22 WO PCT/EP2011/070661 patent/WO2012069462A1/en not_active Ceased
- 2011-11-22 MX MX2013005762A patent/MX341734B/es active IP Right Grant
- 2011-11-22 PL PL11788121.9T patent/PL2643698T3/pl unknown
- 2011-11-22 CA CA2818738A patent/CA2818738A1/en not_active Abandoned
- 2011-11-22 BR BR112013012820A patent/BR112013012820A2/pt active Search and Examination
- 2011-11-22 EP EP11788121.9A patent/EP2643698B1/en active Active
- 2011-11-22 AU AU2011333819A patent/AU2011333819A1/en not_active Abandoned
- 2011-11-22 EA EA201390762A patent/EA201390762A1/ru unknown
- 2011-11-22 CN CN201180056555.2A patent/CN103384827B/zh not_active Expired - Fee Related
-
2014
- 2014-01-17 US US14/158,054 patent/US9389235B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HUE030005T2 (en) | 2017-04-28 |
| JP2014500493A (ja) | 2014-01-09 |
| SG190698A1 (en) | 2013-07-31 |
| GB201021289D0 (en) | 2011-01-26 |
| US9389235B2 (en) | 2016-07-12 |
| US20120128702A1 (en) | 2012-05-24 |
| CN103384827B (zh) | 2016-06-08 |
| BR112013012820A2 (pt) | 2017-05-09 |
| PL2643698T3 (pl) | 2016-12-30 |
| AU2011333819A1 (en) | 2013-05-23 |
| CA2818738A1 (en) | 2012-05-31 |
| KR20130119453A (ko) | 2013-10-31 |
| NZ609712A (en) | 2015-05-29 |
| EA201390762A1 (ru) | 2013-09-30 |
| WO2012069462A1 (en) | 2012-05-31 |
| EP2643698A1 (en) | 2013-10-02 |
| CN103384827A (zh) | 2013-11-06 |
| US20140234347A1 (en) | 2014-08-21 |
| EP2643698B1 (en) | 2016-06-22 |
| MX341734B (es) | 2016-08-31 |
| US8669063B2 (en) | 2014-03-11 |
| MX2013005762A (es) | 2013-08-12 |
| JP6005051B2 (ja) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2592957T3 (es) | Biomarcadores para la predicción de la eficacia de una inmunoterapia contra el cáncer | |
| Fonseca-Sánchez et al. | Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade | |
| Groblewska et al. | Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients | |
| WO2009074350A2 (en) | Serum proteomic for finding diagnostic markers and for monitoring therapeutical intervention in treatment of hepatocellular carcinoma | |
| JP2014500493A5 (enExample) | ||
| Liu et al. | Serum proteomics for gastric cancer | |
| Milman et al. | The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer | |
| Dirican et al. | The effects of hematological parameters and tumor-infiltrating lymphocytes on prognosis in patients with gastric cancer | |
| Jiang et al. | Potential plasma lipid biomarkers in early-stage breast cancer | |
| ES2324128A1 (es) | Metodo para el diagnostico de carcinoma hepatocelular mediante el empleo de marcadores moleculares. | |
| Lai et al. | NIMA-related kinase 2 regulates hepatocellular carcinoma cell growth and proliferation | |
| Wang et al. | Development and application of a double-antibody sandwich ELISA kit for the detection of serum MUC1 in lung cancer patients | |
| Zhang et al. | Expression of interleukin-6 is associated with epithelial-mesenchymal transition and survival rates in gallbladder cancer | |
| Asada et al. | Integrin α6A (ITGA6A)-type splice variant in extracellular vesicles has a potential as a novel marker of the early recurrence of pancreatic cancer | |
| Kim et al. | Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air-liquid interface method | |
| Yeh et al. | The− 174 G/C polymorphism in interleukin-6 (IL-6) promoter region is associated with serum IL-6 and carcinoembryonic antigen levels in patients with colorectal cancers in Taiwan | |
| Barut et al. | Can immature granulocyte predict the prognosis of bladder cancer | |
| Pawlaczyk et al. | A correlation between acute phase proteins and cytokines in patients suffering from mycosis fungoides | |
| Repetto et al. | Proteomic Exploration of Plasma Exosomes and Other Small Extracel‑lular Vesicles in Pediatric Hodgkin Lymphoma: A Potential Source of Biomarkers for Relapse Occurrence. Diagnostics (Basel). 2021; 11 (6): 917 | |
| Li et al. | A neotype nomogram based on accessible clinical indicators to predict the overall survival of esophageal cancer patients underwent radical resection | |
| Tsai et al. | Dickkopf-1 and hepatocellular carcinoma | |
| Scully | Plasma peptidome: A new approach for assessing thrombotic risk? | |
| Lückstädt et al. | CD109 drives pro-tumorigenic cell properties in human non-small cell lung cancer through interaction with desmoglein-2 | |
| Tsukinoki et al. | Immunohistochemical study of DNA topoisomerase type II alpha and Ki-67 in oral squamous cell carcinoma | |
| Zhou et al. | RICH1 enhances pro-inflammatory TAM infiltration in breast cancer via promoting TRIM21-mediated ubiquitination of RhoA and inhibiting STAT3 phosphorylation |